Analyst: Zealand Pharma should benefit from Amylin sale
A price of DKK 40 billion for the Novo Nordisk rival Amylin Pharmaceuticals shows that the market for GLP-1 drugs is on the rise. But it will primarily be detectable in Zealand Pharma’s share price, believes analyst.
Ritzau Finans/ Leonora Beck
Bristol Myers Squibb’s recent acquisition of the former Eli Lilly partner Amylin Pharmaceuticals probably won’t have an effect on the share price of Novo Nordisk. Because, even though the deal could have a positive effect on the value of Novo Nordisk’s GLP-1 segment, the Novo share is already valued fairly high.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75)
